Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Ki Wook | - |
dc.contributor.author | Lee, Hoan Jong | - |
dc.contributor.author | Park, Ji Young | - |
dc.contributor.author | Cho, Hye-Kyung | - |
dc.contributor.author | Kim, Yae-Jean | - |
dc.contributor.author | Kim, Kyung-Hyo | - |
dc.contributor.author | Kim, Nam Hee | - |
dc.contributor.author | Hong, Young Jin | - |
dc.contributor.author | Kim, Dong Ho | - |
dc.contributor.author | Kim, Hwang Min | - |
dc.contributor.author | Cha, Sung-Ho | - |
dc.date.accessioned | 2024-02-14T02:00:33Z | - |
dc.date.available | 2024-02-14T02:00:33Z | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.issn | 1358-8745 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/72015 | - |
dc.description.abstract | Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine (R) (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. (C) 2018 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.vaccine.2018.01.075 | - |
dc.identifier.bibliographicCitation | VACCINE, v.36, no.11, pp 1398 - 1404 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000427212900011 | - |
dc.identifier.scopusid | 2-s2.0-85041510649 | - |
dc.citation.endPage | 1404 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1398 | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 36 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Japanese encephalitis | - |
dc.subject.keywordAuthor | Vaccine | - |
dc.subject.keywordAuthor | Vero cells | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Children | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | PROTECTION | - |
dc.subject.keywordPlus | IMMUNITY | - |
dc.subject.keywordPlus | IC51 | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.